256 related articles for article (PubMed ID: 18686042)
21. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel.
Tornio A; Filppula AM; Backman JT
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():48-59. PubMed ID: 34410044
[TBL] [Abstract][Full Text] [Related]
22. Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.
Nettleton DO; Einolf HJ
Curr Top Med Chem; 2011; 11(4):382-403. PubMed ID: 21320066
[TBL] [Abstract][Full Text] [Related]
23. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes.
Chu I; Favreau L; Soares T; Lin Cc; Nomeir AA
Rapid Commun Mass Spectrom; 2000; 14(4):207-14. PubMed ID: 10669878
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
Xing J; Kirby BJ; Whittington D; Wan Y; Goodlett DR
Drug Metab Dispos; 2012 Sep; 40(9):1757-64. PubMed ID: 22679214
[TBL] [Abstract][Full Text] [Related]
25. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective.
Kumar S; Sharma R; Roychowdhury A
Curr Med Chem; 2012; 19(21):3605-21. PubMed ID: 22680629
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities.
Kosugi Y; Hirabayashi H; Igari T; Fujioka Y; Hara Y; Okuda T; Moriwaki T
Xenobiotica; 2012 Feb; 42(2):127-38. PubMed ID: 22117526
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.
Reinen J; Smit M; Wenker M
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):737-750. PubMed ID: 29785610
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
Giri P; Naidu S; Patel N; Patel H; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
[TBL] [Abstract][Full Text] [Related]
31. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
Venkatakrishnan K; Pickard MD; von Moltke LL
Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome P450 reaction-phenotyping: an industrial perspective.
Zhang H; Davis CD; Sinz MW; Rodrigues AD
Expert Opin Drug Metab Toxicol; 2007 Oct; 3(5):667-87. PubMed ID: 17916054
[TBL] [Abstract][Full Text] [Related]
33. Cytochrome P450s in the development of target-based anticancer drugs.
Purnapatre K; Khattar SK; Saini KS
Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
[TBL] [Abstract][Full Text] [Related]
34. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.
Khojasteh SC; Prabhu S; Kenny JR; Halladay JS; Lu AY
Eur J Drug Metab Pharmacokinet; 2011 Mar; 36(1):1-16. PubMed ID: 21336516
[TBL] [Abstract][Full Text] [Related]
35. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
36. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.
Kenny JR; Mukadam S; Zhang C; Tay S; Collins C; Galetin A; Khojasteh SC
Pharm Res; 2012 Jul; 29(7):1960-76. PubMed ID: 22415140
[TBL] [Abstract][Full Text] [Related]
37. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.
Venkatakrishnan K; Von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 2001 Nov; 41(11):1149-79. PubMed ID: 11697750
[TBL] [Abstract][Full Text] [Related]
38. Comparative inhibition of inducible and constitutive CYPs in rat hepatic microsomes by parathion.
Murray M; Butler AM
Xenobiotica; 2004 Aug; 34(8):723-39. PubMed ID: 15690761
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 inhibition assays using traditional and fluorescent substrates.
Paradise E; Chaturvedi P; Ter-Ovanesyan E
Curr Protoc Pharmacol; 2007 Dec; Chapter 7():Unit7.11. PubMed ID: 21948171
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.
Nakamura K; Ariyoshi N; Iwatsubo T; Fukunaga Y; Higuchi S; Itoh K; Shimada N; Nagashima K; Yokoi T; Yamamoto K; Horiuchi R; Kamataki T
Biol Pharm Bull; 2005 May; 28(5):882-5. PubMed ID: 15863898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
